The FDA has approved Promacta (eltrombopag) for the treatment of thrombocytopenia in children aged ≥6 years with chronic immune thrombocytopenia (ITP) who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy.
Results from a new study suggest that small controlled doses of carbon monoxide may protect the brain from damage after a subarachnoid hemorrhage by speeding up the clearance of heme that accumulates.
The FDA has approved Jadenu (deferasirox) tablets for the treatment of chronic iron overload due to blood transfusions in patients ≥2 years old, and for chronic iron overload in non-transfusion-dependent thalassemia syndromes (NTDT) in patients ≥10 years old.
For patients with atrial fibrillation receiving anticoagulant treatment, the presence of anemia is associated with increased risk of thromboembolic events, bleeding complications, and mortality.
Blood that's been stored for a few weeks is just as beneficial as fresh blood for patients with life-threatening conditions who require transfusions, a new study shows.
Is one erythropoiesis-stimulating agent (ESA) superior to others for treating anemia in patients with chronic kidney disease (CKD)?
The FDA has approved Blincyto (blinatumomab) for the treatment of relapsed or refractory Philadelphia chromosome-negative precursor B-cell acute lymphoblastic leukemia.
Jazz Pharmaceuticals announced that the FDA has approved the IV administration of Erwinaze (asparaginase Erwinia chrysantheum).